BNTX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.2 -- higher than merely 4.26% of US-listed equities with positive expected earnings growth.
BNTX's went public 1.04 years ago, making it older than only 0.38% of listed US stocks we're tracking.
BNTX's price/sales ratio is 164.88; that's higher than the P/S ratio of 97.91% of US stocks.
Stocks that are quantitatively similar to BNTX, based on their financial statements, market capitalization, and price volatility, are MRNA, ANAB, BGNE, INCY, and ARGX.
BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders.
DUBLIN, Oct. 2, 2020 /PRNewswire/ -- ResearchAndMarkets.com published a new article on the vaccine industry "COVID-19 Vaccine Trials are Entering the Final Stage of Development" Johnson & Johnson has begun final stage testing of its COVID-19 vaccine candidate. The company will trial the…
DUBLIN--(BUSINESS WIRE)--The "COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020" report has been added to ResearchAndMarkets.com's offering. COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 provides the strategists, marketers and senior management with the critical information they need to assess the global COVID-19 vaccine & therapeutics clinical trial analysis 2020 market. Major players in the COVID-19 vaccine and therapeutics clinical trial analysis market
Several coronavirus vaccine trials will soon be finished and some of the frontrunners might be deemed safe and effective for emergency use. Health officials from the World Health Organization and Dr. Anthony Fauci warn that the arrival of COVID-19 vaccines won't be enough to reduce the transmission of the illness anytime soon. Fauci says that precautionary measures including face masks, social distancing, and frequent handwashing will need to continue even after vaccines arrive. The FDA will host a significant coronavirus vaccine meeting in just a few weeks, at which point we might find out more details about the progress of experimental drugs that have reached the final phase of testing. Vaccine candidates from AstraZeneca/Oxford, Pfizer/BioNTech, and Moderna have Phase 3 trials underw...
It’s not the fruitloop anti-vaxxers fault, either. It’s governments. Via Bloomberg: The Covid-19 vaccine trial designed by Pfizer Inc. and its German partner BioNTech SE may allow them to find whether their shot works before their fastest-moving rivals. The companies plan a first look after a mere 32 coronavirus infections have accumulated in their massive
Experts Worry As Leading COVID-19 Vaccines Adopt Trial Shortcuts In "Rush For Results" Tyler Durden Tue, 09/22/2020 - 13:05 As doubts about the FDA's credibility grow as the agency awaits the initial results from the frontrunner's "Phase 3" trials, the leading vaccine makers are working to further expedite the approval process by streamlining procedures to try and make a determination about whether their vaccine "works or not" within the next month or so. The issue, as Bloomberg reports , is that the leading vaccine companies are shooting for low targets for the number of confirmed infections among the tens of thousands of patients they've recruited for their trials. Remember, half of the test subjects have been given a vaccine, while the other half haven't. Leading candidates will repo...